A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD

Inclusion Criteria:

- COPD diagnosis defined by ATS/ERS

- Former or current smoker

- A measured aortic pulse wave velocity = or > 11.0 m/s at Screening

Exclusion Criteria:

- Pregnancy

- A current diagnosis of asthma

- alpha1-antitrypsin deficiency as the underlying cause of COPD

- subjects with other and active respiratory disorders

- A cardiovascular event occurred in the 6 months prior to Visit 1

- Current severe heart failure (New York Heart Association Class IV) and have a known
ejection fraction of < 30 %

- Clinical significant and uncontrolled hypertension

- Abnormal and clinical significant 12-lead ECG findings at Visit 1

- Have lung volume reduction or lung transplantation within 12 months prior to Visit 1

- Poorly controlled COPD: Acute worsening of COPD that is managed by subject with
antibiotics or corticosteroids, or requires treatment prescribed by a physician in the
6 weeks prior to Visit 1; or subject needs to be hospitalised due to poorly controlled
COPD within 12 weeks prior to Visit 1

- Lower respiratory tract infection that required use of antibiotics within 6 weeks
prior to Visit 1

- Participate in the acute phase of a pulmonary rehabilitation within 4 weeks prior to
Visit 1 or who will enter the acute phase of pulmonary rehabilitation during the
study.

- Other diseases or abnormalities in the opinion of the investigator would put safety of
the subject at risk through participation; or would affect the safety or efficacy
analysis if the disease/condition exacerbated during the study.

- subjects with carcinoma has not been in complete remission for at least 5 years.
Carcinoma in site of the cervix, squamous cell carcinoma and basal cell carcinoma of
the skin would not be excluded if the subject has been considered cured within 5 years
since diagnosis.

- subjects with a history of hypersensitivity to any of the study medications or
components of the inhalation powder.

- subjects with a known or suspected history of alcohol or drug abuse within the last 2
years prior to Screening

- subjects are medically unable to withhold albuterol or ipratropium for 4 hours prior
to spirometry testing at each study visit

- subjects are medically unable to stop the 'excluded medications' listed in the
protocol

- subjects started, discontinued certain medications listed in the protocol or have not
been on a stable dose in the past three months prior to Screening, or are not
anticipated to remain on a stable dose during the study treatment period.

- Long term oxygen therapy requiring >12 hour per day or a flow rate > 2 L/min

- A body mass index = or >35 kg/m2

- Fasting lipid level LDL>3.3 mmol/L, total cholesterol >5.2 mmol/L, and triglycerides >
2.24mmol/L

- Non-compliance

- Questionable validity of consent

- Prior use of study medication or other investigational drugs.

- Affiliation with investigator site